SELLAS Life Sciences Group Inc.
SLS | NASDAQ
$11.79
+$0.42 (+3.69%)
Sep 22, 2026, 12:30 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | 1M | 7.6M | 1.9M |
Cost of Revenue | n/a | n/a | n/a | 100K | 200K | n/a |
Gross Profit | n/a | n/a | n/a | 900K | 7.4M | 1.9M |
Operating Income | -28.27M | -31.51M | -37.87M | -41.95M | -25.29M | -16.98M |
Interest Income | 1.41M | 632K | 525K | 317K | 6K | 26K |
Pretax Income | -26.86M | -30.88M | -37.34M | -41.3M | -20.94M | -16.77M |
Net Income | -26.86M | -30.88M | -37.34M | -41.3M | -20.7M | -16.76M |
Selling & General & Admin | 12.25M | 12.42M | 13.86M | 12.58M | 11.32M | 9.6M |
Research & Development | 16.02M | 19.1M | 24.01M | 30.27M | 21.37M | 9.28M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 28.27M | 31.51M | 37.87M | 42.85M | 32.69M | 18.88M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 28.27M | 31.51M | 37.87M | 42.95M | 32.89M | 18.88M |
Income Tax Expense | n/a | n/a | n/a | n/a | -237K | -17K |
Shares Outstanding (Basic) | 109.05M | 61.2M | 27.78M | 19.4M | 15.48M | 7.94M |
Shares Outstanding (Diluted) | 109.05M | 61.2M | 27.78M | 19.4M | 15.48M | 7.98M |
EPS (Basic) | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 |
EPS (Diluted) | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 |
EBITDA | -26.86M | 632K | 529K | -31.49M | -18.32M | -16.4M |
EBIT | -26.86M | -30.88M | -37.34M | -31.95M | -19.59M | -16.77M |
Depreciation & Amortization | n/a | 31.51M | 37.87M | 457K | 1.27M | 377K |
Add to Watchlist
Select watchlists to add or remove SLS